1White DL,Kanwal F,El-Serag HB.Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer,based on systematic review[J].Clin Gastroenterol Hepatol,2012,10(12):1 342.
2Fattovich G,Stroffolini T,Zagni I,et al.Hepatocellular carcinoma in cirrhosis:incidence and risk factors[J].Gastroenterology,2004,127(5):35.
3Chen G,Lin W,Shen F,et al.Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study[J].Am J Gastroenterol,2006,101(8):1 797.
4Lee MH,Yang HI,Lu SN,et al.Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma:long-term predictors from a community-based cohort study[J].J Clin Oncol,2010,28(30):4 587.
5Tian S,Hui X,Fan Z,et al.Suppression of hepatocellular carcinoma proliferation and hepatitis B surface antigen secretion with interferon-λ1 or PEG-interferon-λ1[J].FASEB J,2014,28(8),3 528.
6Boyd A,Gozlan J,Maylin S,et al.Persistent viremia in HIV hepatitis B coinfected patients undergoing long-term tenofovir:virological and clinical implications[J].Hepatology,2014,60(2),497.
7Bruix J,Sherman M.Management of hepatocellular carcinoma:An update[J].AASLD Practice Guidelines,2010,53(3):1 020.
9Zhao M,He HW,Sun HX,et al.Dual knockdown of Nras and epiregulin synergistically suppressed the growth of human hepatoma cells[J].Biochem Biophys Res Commun,2009,387(2):239.
10Jeon YE,Lee SC,Paik SS,et al Histology-directed matrix-assisted laser desorption/ionization analysis reveals tissue origin and p53 status of primary liver cancers[J].Pathol Int,2011,61(8):449.
二级参考文献64
1Peng Yan,Lu-Nan Yan the Department of Surgery, Pittsburg Medical College of USA First People’s Hospital of Chengdu, Chengdu 610041, China Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.Staging of hepatocellular carcinoma[J].Hepatobiliary & Pancreatic Diseases International,2003,2(4):491-495. 被引量：2
9LLOVET JM, RICCI S, MAZZAFERRO V,et al. Sorafenib in advanced hepatocel|ular carcinoma[J]. N Engl J Med,2008,359 (4) :378 -390.
10RAOUL J, SANTORO A, BEAUGRAND M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to ECOG performance status: A subanalysis from the SHARP trial[J]. J Clin Oncol, 2008,26(19) :4857.
